TickerGuard
Buy Day today: Neutral (57) Mixed market breadth · no major macro event
ALNY

Alnylam Pharmaceuticals Inc

Healthcare · Biotechnology

232.70$ +3.6% vs. previous close Closing price · As of: Oct 9, 2026

Statements

Balance Sheet

Alnylam Pharmaceuticals Inc (ALNY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 5,559 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ALNY
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
1,313 1,263 1,134 1,434 1,358 1,995 1,923 1,789 1,676 1,575 2,014 2,716 2,542 2,395 2,280 3,374 3,307 3,407 3,255 3,509 3,472 3,643 3,434 3,330 3,535 3,546 3,392 3,402 3,839 3,830 3,824 4,010 4,205 4,240 4,214 4,566 4,852 4,966 5,130 5,559
748 989 597 961 993 1,783 1,691 1,503 1,342 1,209 1,392 2,064 1,897 1,716 1,585 2,160 2,055 2,615 1,970 2,725 2,675 2,809 2,590 2,472 2,691 2,692 2,541 2,524 2,985 2,983 2,989 3,173 3,355 3,295 3,268 3,644 3,953 4,051 4,219 4,620
168 194 171 409 202 645 396 361 317 420 725 1,136 923 547 468 581 497 497 380 746 1,094 820 534 576 1,073 866 672 658 1,033 813 682 968 1,100 966 1,020 1,114 1,490 1,657 1,711 1,708
713 943 560 923 948 1,705 1,569 1,448 1,237 1,083 1,245 1,927 1,721 1,536 1,342 1,926 1,834 1,874 1,710 1,900 2,328 2,436 2,240 2,111 2,265 2,192 2,071 2,058 2,406 2,439 2,371 2,625 2,780 2,695 2,632 2,858 2,725 2,908 3,009 3,308
15 23 19 15 15 34 51 3.0 3.4 19 34 31 48 43 76 69 79 602 111 647 141 199 157 142 185 238 219 221 325 328 321 309 354 405 418 567 965 778 884 913
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11 24 32 41 55 56 68 77 67 75 74 84 98 86 79 89 115 129 132 100 96 89 94 84 76 79 66 72 75 83 84 97
74 115 130 148 162 182 202 228 273 321 342 372 396 425 430 439 445 465 702 709 721 502 504 732 515 523 523 527 729 – – – – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – 698 – – – – – – – 594 – –
298 343 303 311 299 228 168 169 198 273 467 959 935 956 930 1,975 2,092 2,391 2,329 2,656 2,716 3,055 3,032 3,154 3,603 3,705 3,651 3,811 4,005 4,051 4,044 4,013 4,173 4,173 4,098 4,315 4,618 4,177 4,054 4,205
82 193 96 109 101 198 138 114 122 243 149 329 353 353 339 384 480 585 495 555 611 696 606 658 773 768 673 789 950 968 942 1,055 1,221 1,186 1,076 1,301 1,555 1,466 1,349 1,513
– 11 150 150 150 11 15 30 – 63 17 29 28 28 29 33 32 37 39 39 41 41 41 41 42 42 43 42 42 42 42 42 42 42 46 46 45 46 46 46
23 54 25 23 9.2 28 13 12 22 60 23 71 39 50 40 26 28 52 45 53 40 73 55 52 41 98 62 60 74 56 78 74 71 88 97 102 118 116 127 108
150 150 150 150 150 30 30 30 30 30 30 30 – – – – – 191 192 433 434 676 677 678 1,016 1,017 1,018 1,019 1,020 1,021 1,022 1,023 1,024 1,025 1,026 1,027 1,040 1,008 1,009 1,011
1,015 920 831 1,123 1,059 1,766 1,755 1,621 1,478 1,302 1,547 1,757 1,607 1,439 1,350 1,400 1,215 1,016 926 853 756 588 401 176 -68 -158 -259 -408 -166 -221 -219 -3.1 32 67 115 251 234 789 1,075 1,354
-1,544 -1,657 -1,764 -1,883 -2,005 -2,148 -2,221 -2,384 -2,630 -2,841 -3,023 -3,242 -3,451 -3,727 -3,909 -4,089 -4,342 -4,585 -4,786 -4,975 -5,180 -5,438 -5,679 -5,956 -6,362 -6,569 -6,743 -7,019 -6,872 -7,010 -7,076 -7,092 -7,204 -7,288 -7,345 -7,412 -7,160 -6,703 -6,497 -6,332
86 86 86 88 92 96 100 101 101 101 105 109 109 112 113 115 116 116 117 118 119 120 120 121 122 123 124 125 131 126 126 127 129 129 130 130 137 136 138 138

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?